About Amgen

You are leaving Amgevita.EU website and entering another Amgen website

You are leaving Amgevita.EU website and entering another Amgen website

You are now leaving Amgevita.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

AMGEN: EMBRACING THE FUTURE
WITH A LEGACY IN BIOLOGICS

AMGEVITA®: A continuation of Amgen’s legacy in inflammatory disease

Amgen has nearly four decades of experience in developing and supplying innovator biologics dedicated to serving every patient every time. Amgen is committed to delivering high-value health solutions in inflammatory disease.1,2
Image showing Amgen's legacy in inflammatory disease.
About Amgen
Read more
*Marketed by Amgen in the US and Canada; by Pfizer in Europe.
†Commercially available in the US from July 2019.
  1. Amgen Products. Available at: www.amgen.com/products/. Last accessed May 2020.
  2. Amgen Biosimilars. Available at: www.amgenbiosimilars.com. Last accessed May 2020.

Home

SmPC

footerbg

AMGEVITA® is authorised for the following indications by the European Commission:
AMGEVITA® is an adalimumab biosimilar indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.
> See full indication
AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.